Wall Street analysts predict that Kindred Biosciences Inc (NASDAQ:KIN) will report sales of $1.45 million for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Kindred Biosciences’ earnings, with estimates ranging from $1.40 million to $1.50 million. Kindred Biosciences reported sales of $1.33 million during the same quarter last year, which indicates a positive year-over-year growth rate of 9%. The company is scheduled to issue its next earnings report on Wednesday, March 4th.
According to Zacks, analysts expect that Kindred Biosciences will report full year sales of $4.27 million for the current fiscal year, with estimates ranging from $4.13 million to $4.40 million. For the next financial year, analysts expect that the company will post sales of $10.97 million, with estimates ranging from $8.80 million to $13.14 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that cover Kindred Biosciences.
Kindred Biosciences (NASDAQ:KIN) last posted its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.02). The company had revenue of $1.10 million during the quarter, compared to the consensus estimate of $1.55 million. Kindred Biosciences had a negative return on equity of 58.86% and a negative net margin of 1,461.28%.
Shares of KIN stock traded up $0.05 on Thursday, reaching $7.82. The company had a trading volume of 75,414 shares, compared to its average volume of 175,508. The business’s 50-day moving average is $8.01 and its 200 day moving average is $7.63. Kindred Biosciences has a one year low of $5.96 and a one year high of $12.99. The company has a quick ratio of 8.88, a current ratio of 9.30 and a debt-to-equity ratio of 0.21. The stock has a market capitalization of $304.51 million, a PE ratio of -4.89 and a beta of 0.42.
A number of large investors have recently added to or reduced their stakes in KIN. Marshall Wace LLP acquired a new stake in Kindred Biosciences during the 1st quarter valued at approximately $53,000. Aperio Group LLC acquired a new stake in Kindred Biosciences during the 2nd quarter valued at approximately $115,000. General American Investors Co. Inc. increased its position in Kindred Biosciences by 10.0% during the 2nd quarter. General American Investors Co. Inc. now owns 494,327 shares of the biopharmaceutical company’s stock valued at $4,118,000 after purchasing an additional 44,753 shares during the period. Gabelli Funds LLC acquired a new stake in Kindred Biosciences during the 2nd quarter valued at approximately $108,000. Finally, PARK CIRCLE Co acquired a new stake in Kindred Biosciences during the 2nd quarter valued at approximately $27,000. 67.37% of the stock is owned by institutional investors and hedge funds.
About Kindred Biosciences
Kindred Biosciences, Inc, a commercial-stage biopharmaceutical company, focusing on developing therapies for pets. Its product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats.
Recommended Story: Put Option Volume
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kindred Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.